TLA-based targeted sequencing provides breakpoint sequences resulting from structural changes or gene fusions.
These breakpoint sequences can be the basis for personalised qPCR-based minimal residual disease tests.
Minimal residual disease (MRD) tests are used to determine prognosis and response to therapy in acute and chronic leukaemia, lymphoma and myeloma patients.
Cergentis supports the development of personalised MRD tests with its kits and services.
Examples of the use of genomic breakpoint sequences in qPCR-based minimal residual disease tests by leading European diagnostic labs are presented in the application note below.
"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”Alfredo Brusco Ph.D.(Department of Medical Sciences, University of Turin, Italy)
"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”Jules Meijerink Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)
"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unravelled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”Pieter van Vlierberghe Ph.D.(Center for Medical Genetics, Ghent University, Belgium)
"We conclude that TLA is an effective method for the reliable detection of sequence mutations and structural variations that are relevant for disease prognosis in pediatric leukemia.”Roland Kuiper Ph.D.(Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands)